PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-7.89%
Cash & equivalents declining -7.89% while RVPH's grows 95.93%. Howard Marks would question why our liquidity is shrinking while competitor builds cash.
No Data
No Data available this quarter, please select a different quarter.
-7.89%
Below half of RVPH's 95.93%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-7.62%
Below half of RVPH's 72.84%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
-4.83%
Both RVPH and the company show zero PP&E (Net) Growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-3.38%
Both RVPH and the company show zero Total Non-Current Assets Growth.
No Data
No Data available this quarter, please select a different quarter.
-7.59%
Below half of RVPH's 64.40%. Michael Burry sees a potential red flag for stagnation or capital shortage.
-25.56%
Less than half of RVPH's 5.25%. David Dodd sees a more disciplined AP approach or lower volume.
-49.71%
Similar yoy changes to RVPH's -49.51%. Walter Schloss finds a parallel approach to short-term funding.
No Data
No Data available this quarter, please select a different quarter.
240.62%
Higher Deferred Revenue (Current) Growth compared to RVPH's zero value, indicating better performance.
-18.75%
Less than half of RVPH's 8.21%. David Dodd sees fewer expansions in other current obligations.
-24.27%
Less than half of RVPH's 4.94%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-24.27%
Less than half of RVPH's 4.83%. David Dodd sees far fewer liability expansions relative to competitor.
5.27%
Less than half of RVPH's 45.49%. David Dodd sees fewer share issuances vs. competitor.
-5.68%
≥ 1.5x RVPH's -3.55%. David Dodd sees higher yoy retained profits than competitor.
-17.53%
Higher AOCI Growth compared to RVPH's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-4.86%
Below half RVPH's 89.71%. Michael Burry sees potential underperformance in building shareholder capital.
-7.59%
Below half RVPH's 64.40%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
-49.71%
Similar yoy changes to RVPH's -49.51%. Walter Schloss notes parallel total debt strategies.
7.55%
Less than half of RVPH's -102.37%. David Dodd sees better deleveraging or stronger cash buildup than competitor.